|
Inspire Pharmaceuticals, Inc.; 4222 Emperor Boulevard, Suite 200; Durham, NC 27703 ... Inspire Announces Webcast of Presentation at Piper Jaffray Health Care Conference; DURHAM, N.C.--(BUSINESS WIRE)--Nov. 25, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today...
|
www.inspirepharm.com/about/contact.php
www.inspirepharm.com/about/contact.php
|
|
|
Inspire Pharmaceuticals at Piper Jaffray Healthcare Conference ... 25, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, and Thomas R. Staab, II, CFO and Treasurer, will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday,
|
ir.inspirepharm.com/
ir.inspirepharm.com/
|
|
|
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the initiation of a Phase 3 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis. This ... Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products...
|
www.medicalnewstoday.com/articles/90323.php
|
|
|
Get detailed information on Inspire Pharmaceuticals, Inc. (ISPH) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company headlines. ... Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing,
|
finance.yahoo.com/q?s=ISPH
|
|
DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire w ... Investor Contact:; Inspire Pharmaceuticals, Inc.; Jenny Kobin, VP, Investor Relations and Corporate Communications; 919-941-9777, Ext. 219 or;
|
www.drugs.com/clinical_trials/inspire-announces-present...
www.drugs.com/clinical_trials/inspire-announces-presentations-2007-association-research-vision-ophthalmology-annual-meeting-798.html
|
|
DURHAM, NORTH CAROLINA - January 30, 2004 - Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) met with the Food and Drug Administration (FDA) on January 29th regarding the approvable letter received on December 19, 2003 for diquafosol tetrasodium ophthalmic solution for the treatment of dry eye.
|
www.drugs.com/nda/prolacria_040130.html
|
|
Inspire Pharmaceuticals, Inc. (ISPH) Announces Webcast of Presentation at Piper Jaffray Health Care Conference 11/25/2009 8:11:42 AM More... ... Inspire Pharmaceuticals, Inc. (ISPH) Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis 11/4/2009 9:31:44...
|
www.biospace.com/company_profile.aspx?CompanyId=3172
|
|
Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). ... If not treated,
|
www.news-medical.net/news/20090910/Inspire-Pharmaceutic...
www.news-medical.net/news/20090910/Inspire-Pharmaceuticals-to-increase-production-of-azithromycin-ophthalmic-solution.aspx
|
|
Inspire connects patients, families, friends, caregivers and health professionals for health and wellness support. Connect with others who know what you're going through. ... Join over 50 health organizations -- partner with Inspire to create a support group for your members...
|
www.inspire.com/
www.inspire.com/
|
|
